Full-Time

Manager Clinical Quality Investigations

Confirmed live in the last 24 hours

Medpace, Inc.

Medpace, Inc.

1,001-5,000 employees

No salary listed

Senior

Cincinnati, OH, USA

Location could be any country in EST and CET time zones; other US East Coast locations or a home-based position may be considered.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Data Analysis
Google Cloud Platform
Requirements
  • Bachelor’s degree required (a more advanced degree preferred) in science or a related field.
  • At least five (5) years of QA experience in a GCP regulated environment (a combination of experience in GxP regulated environment, including GCP will also be considered).
  • Experience in problem solving through investigation, root cause analysis and CAPA planning.
  • Strong analytical skills.
  • Strong quality mindset.
  • Excellent written and verbal communications skills in English.
  • Independent thinking and planning ability.
  • Good time management skills.
  • Ability to switch between both big picture view and attention to detail.
  • Ability to develop strong collaborative working relationships with key stakeholders.
  • The ability to work well on a team as well as independently.
Responsibilities
  • Facilitating management of Quality Investigations and identification and evaluation of risks and process improvements through application of the Medpace Quality Event Management (QEM) program.
  • Deliver high-quality QI investigations, root cause analyses and risk assessments.
  • Partner with Management Designees, and operational Subject Matter Experts across all steps of the QEM process to facilitate robust corrective and preventive actions required to prevent recurrence of issues.
  • Determine the most appropriate process for investigating and documenting Quality Events as part of triage.
  • Provide training on how to conduct Quality Investigations.
  • Conduct risk-based, independent Process Walkthroughs as part of QE investigations and root cause analyses.
  • Conduct CAPA effectiveness check audits where required.
  • Share lessons learned with affected teams through delivery of case study workshops and case study lectures.
  • Contribute to the QEM Program through maintaining Controlled Documents, Guidelines, Templates and associated training for Medpace staff.
  • Maintain oversight on assignments, timely progression, and completion of QIs through the monitoring of Business Intelligence dashboards.
  • Develop executive summaries of significant QIs for senior management, the President, and the CEO.
  • Provide support to Medpace QA staff hosting external audits and regulatory inspections by addressing auditors'/inspectors' questions and/or provide QEM expertise.
  • Utilize a categorization system and Business Intelligence tool to facilitate identification of process and system level trends and risks across all regulated Medpace Business Entities and Functional Areas (FAs).
  • Facilitate reliable and repeatable categorization of QA data.
  • Assist in maintaining a data trending and analysis schedule for Medpace core processes.
  • Coordinate and perform scheduled or ad hoc reviews of QA data, assess risks (likelihood, impact, detectability) and share actionable insights and recommendations with Medpace stakeholders (e.g. Process Owner, Training and Development, Process Improvement).
  • Provide data-driven support to the development of risk-based internal process audit schedules across Medpace Business Entities.
  • Provide data-driven support to the development of internal process audit plans and contribute to audit conduct and reporting.
Desired Qualifications
  • Experience in quality risk management is a plus.
  • Experience with a wide range of computerized systems including MS Office (experience with Business Intelligence tools is a plus).

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Irving, Texas

Founded

1992

Simplify Jobs

Simplify's Take

What believers are saying

  • Significant revenue growth in Q4 2023 indicates strong market demand and effective strategies.
  • Recent investments by financial institutions reflect confidence in Medpace's growth potential.
  • Expansion of medical leadership team suggests increased focus on clinical research and development.

What critics are saying

  • Increased competition from Lantheus and others may pressure Medpace's market share.
  • New Cincinnati office construction could lead to higher operational costs and project delays.
  • Decreased net income margin in 2023 indicates challenges in maintaining profitability.

What makes Medpace, Inc. unique

  • Medpace's expansion in infectious diseases and vaccines shows strategic focus on high-demand sectors.
  • New leadership in respiratory and women's health enhances Medpace's expertise and service offerings.
  • Commitment to infrastructure growth with new Cincinnati office supports future operational efficiency.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Unlimited Paid Time Off

Competitive Compensation and Benefits Package

Employee Health and Wellness Initiatives

Hybrid Work Options

Structured Career Paths with Opportunities for Professional Growth

Company News

Financial Modeling Prep
Feb 28th, 2025
Lantheus Holdings, Inc. (NASDAQ:LNTH) Demonstrates Strong Capital Efficiency

Lantheus competes with other companies in the medical and pharmaceutical industries, such as ShockWave Medical, Medpace Holdings, LivaNova, Apellis Pharmaceuticals, and Natera.

Stock Titan
Aug 15th, 2024
Skanska builds new office building in Cincinnati, Ohio, USA, for USD 164M, about SEK 1.7 billion

STOCKHOLM, Aug. 15, 2024 /PRNewswire/ - Skanska has signed a contract with Medpace, a clinical research company, for the construction of a new office building in Cincinnati, Ohio, USA.

MarketBeat
Apr 8th, 2024
First National Bank of Hutchinson Invests $786,000 in Medpace Holdings, Inc. (NASDAQ:MEDP)

First National Bank of Hutchinson invests $786,000 in Medpace Holdings, Inc. (NASDAQ:MEDP).

PharmiWeb
Feb 13th, 2024
Medpace Holdings, Inc. Reports Fourth Quarter And Full Year 2023 Results

Revenue of $498.4 million in the fourth quarter of 2023 increased 26.5% from revenue of $394.1 million for the comparable prior-year period, representing a backlog conversion rate of 18.5%.Net new business awards were $614.7 million in the fourth quarter of 2023, representing an increase of 26.7% from net new business awards of $485.1 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.23x.Fourth quarter of 2023 GAAP net income was $78.3 million, or $2.46 per diluted share, versus GAAP net income of $68.7 million, or $2.12 per diluted share, for the comparable prior-year period. Net income margin was 15.7% and 17.4% for the fourth quarter of 2023 and 2022, respectively.EBITDA was $95.8 million for the fourth quarter of 2023, an increase of 19.2% from EBITDA of $80.4 million for the comparable prior-year period, resulting in an EBITDA margin of 19.2%. CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 Financial Results

MarketBeat
Feb 2nd, 2024
Hussman Strategic Advisors Inc. Invests $1.02 Million in Medpace Holdings, Inc. (NASDAQ:MEDP)

Hussman Strategic Advisors Inc. invests $1.02 million in Medpace Holdings, Inc. (NASDAQ:MEDP).